We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Siemens Healthineers - Laboratory Diagnostics

Provides advanced laboratory diagnostics solutions for the medical industry read more Featured Products: More products

Download Mobile App




Preoperative Blood Cell Ratios Predict Endometrial Cancer Survival

By LabMedica International staff writers
Posted on 02 Aug 2015
Print article
The ADVIA 2120 Hematology System
The ADVIA 2120 Hematology System (Photo courtesy of Siemens Healthineers - Laboratory Diagnostics)
The variations in systemic inflammatory response biomarker levels have been associated with adverse clinical outcome in various malignancies and the host response to malignant tumors is characterized by systemic inflammation, resulting in a relative thrombocytosis, neutrophilia and lymphocytopenia.

Biomarkers of systemic inflammation such as elevated neutrophil:lymphocyte ratio (NLR), platelet:lymphocyte ratio (PLR) and absolute monocyte counts have shown potential for guiding the clinical management of cancer patients across a range of malignancies including endometrial cancer.

Scientists at St James’s University Hospital (Leeds, UK) performed a retrospective study examining the records of a sequential series of 733 patients with a new diagnosis of primary endometrial cancer between January 2005 and December 2007. Patients’ full blood count data, including absolute leukocyte, neutrophil, eosinophil, basophil, monocyte, lymphocyte and platelet counts, were collected from a time frame of less than two weeks prior to hysterectomy and used to calculate NLR, PLR and monocyte:lymphocyte (MLR) ratios. The investigators chose to calculate MLR, the reciprocal of the more frequently used lymphocyte:monocyte ratio (LMR), to standardize by dividing myeloid lineage counts by lymphoid lineage cell counts for all relevant variables.

Full blood counts were performed on the Advia 2120 hematology analyzer (Siemens; Erlangen, Germany). The team applied cut-offs of greater than or equal to 2.4 (NLR), greater than or equal to 240 (PLR) and greater than or equal to 0.19 (MLR). NLR and PLR, but not MLR had independent prognostic significance. They combined NLR and PLR scores and stratified patients into low (NLR-low and PLR-low), intermediate (NLR-high or PLR-high) and high risk (NLR-high and PLR-high) groups. Increased NLR and PLR were most strongly associated with advanced stage, whereas increased MLR was strongly associated with older age. Both NLR and PLR were identified as having independent prognostic value when adjusted for age, stage, grade, lymphovascular space invasion and histopathological subtype.

The authors concluded that they have highlighted the potential of NLR and PLR as additional prognostic tools and despite their inter-relationships, both NLR and PLR proved to be better prognostic indicators than MLR in endometrial cancer. These are simple measures which are essentially cost-neutral and which could aid decision-making in the clinical management of endometrial cancer patients. The study was published on June 16, 2015, in the British Journal of Cancer.

Related Links:

St James’s University Hospital 



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.